Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?

Antonio Russo, Francesco Passiglia, Marta Castiglia, Giuseppe Bronte, Evelien Smits, Edgardo S Santos, Marta Castiglia, Francesco Passiglia, Annelies Janssens, Patrick Pauwels, Christian Rolfo, Luis Raez, Giovanni Sortino

Risultato della ricerca: Articlepeer review

21 Citazioni (Scopus)


Immunotherapy has been studied for many years in lung cancer without significant results, making the majority of oncologists quite skeptical about its possible application for non-small cell lung cancer treatment. However, the recent knowledge about immune escape and subsequent 'cancer immunoediting' has yielded the development of new strategies of cancer immunotherapy, heralding a new era of lung cancer treatment. Cancer vaccines, including both whole-cell and peptide vaccines have been tested both in early and advanced stages of non-small cell lung cancer. New immunomodulatory agents, including anti-CTLA4, anti-PD1/PDL1 monoclonal antibodies, have been investigated as monotherapy in metastatic lung cancer. To date, these treatments have shown impressive results of efficacy and tolerability in early clinical trials, leading to testing in several large, randomized Phase III trials. As these results will be confirmed, these drugs will be available in the near future, offering new exciting therapeutic options for lung cancer treatment.
Lingua originaleEnglish
pagine (da-a)1173-1187
Numero di pagine15
RivistaExpert Review of Anticancer Therapy
Stato di pubblicazionePublished - 2014

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2730???
  • ???subjectarea.asjc.2700.2736???


Entra nei temi di ricerca di 'Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?'. Insieme formano una fingerprint unica.

Cita questo